Can we start? Okay. All right, everyone. Thank you for joining us for the next one. My name is Ben Burnett, Biotechnology Analyst at Wells Fargo. Pleased to be here with the PTC Therapeutics management team. We have, to my left, Matthew Klein, CEO, and to his left, Pierre Gravier, CFO. Thank you all.
Thank you, Ben. Great to be here.
I think maybe just to kick it off, I would ask you, what is the main message you want to leave us with here, and what are the key catalysts we should focus on?
Yeah, absolutely. Look, I think we're incredibly excited for the company's position today. We're exactly where we want to be. As we planned over the past couple of years to really transform the company, into the diversified, valuable, rare disease company we believe it could be. The Upstaza launch, we're now one year in, is off to a tremendous start. We remain exactly on the trajectory we believe we need to be on to get to that $2 billion-plus revenue potential. We're doing this in the context of a year where we believe that we can reach the important cash flow breakeven milestone, which really sets us up for future profitability. We have over $2 billion in cash in the bank.
The R&D portfolio is coming along quite well with the votoplam HD program, the Friedreich's ataxia program, with the recently acquired Fabry gene therapy program, as well as great progress from our splicing and inflammation platforms. We believe we are in a really strong position in terms of current revenue, future revenue growth, and a very strong financial position, which gives us incredible optionality, not only to pursue activities with our current assets, but also continue to look at business development opportunities that can bring short and medium-term top-line growth.
Okay. Excellent. I want to start with PKU, and like you mentioned, you have been in the market now for a little while, still somewhat early days, but you are penetrated into a lot of the centers of excellence. I think we have seen maybe enough time for some patients to kind of come in and come in again for checkups, and so maybe a little bit more feedback. What is the feedback you are getting from the treating physicians about their experience with SUFIANCE, and I guess, what does that tell you about kind of your expectations for sort of future growth? Maybe we will start with the U.S.
Yeah. I would say across the board, we are incredibly excited about the performance to date. Now we are about a year into the launch globally. First, the fact that it is a global launch and that we were able to launch in the U.S. and Europe and Japan within about six months of each other, which is pretty remarkable to be able to do that. I think most importantly is the incredibly positive feedback we are getting in terms of patient experience. When we started talking a lot about SUFIANCE, we said this is a very unique opportunity. This is a drug that has a dual mechanism of action. It is oral, it is well-tolerated, and it is able to provide potential important benefits for the full spectrum of PKU patients.
While there have been previous approved therapies, there still remained a significant unmet need for the vast majority of the 17,000 patients in the U.S. and 58,000 patients in the sort of the global markets where we think we could commercialize. What we have seen so far, again, has been positive. One, we have seen a number of patients return to clinic. If you go back a year from now, we had this conversation and everyone was saying, "Well, the launch is going to start with individuals who are on KUVAN, and they are going to get switched, and that is going to be the lion's share, the early part of the launch." Not the case. In fact, what we saw was the opposite. We saw an interest in getting individuals, kids and adults, who are not on a therapy onto a therapy.
We've seen individuals who've been remote to the clinics, therapy-naive adults who many believed would be very hard to get on drug. We ourselves believed this would be a goal for the latter part of the launch. They've come in and they've made up at this point about 25%-30% of the patients on drug. That's really, really good. A number of patients who've tried and failed are coming back in. We're hearing about the benefits, not only in terms of phenylalanine lowering, which is important in and of itself, but hearing great stories, seeing case reports and case series coming out of individuals being able to liberalize their diet, enjoy foods they never were able to enjoy before. Some folks being able to be completely liberalized.
This includes not only individuals with what are known as BH4 responsive mutations, but also those with classical and more severe patients. So in a nutshell, in this year, we've been able to access not only all, as you mentioned, 100% of the centers of excellence in the U.S., but every key market segment. Therapy-naive patients, tried and failed patients, switch patients from existing therapies, patients with non-BH4 responsive mutations, patients with classical PKU. I think that breadth at this stage of a rare disease launch is very impressive. What we're seeing now, I think we've said we probably have over 2,000 prescription patient start forms in the U.S. That leaves about 15,000 more or roughly.
We think we have a very long way to go, and to have established this foothold in every segment tells us the work now is to just go deeper and deeper into every segment rather than have to sort of create new ones. That's why we're so bullish on the opportunity.
It's fascinating, just the commentary around the expectations for which patient segment would be kind of early contributors to the launch. With regards to the KUVAN switches, when did they become kind of a bigger factor, and what drives that adoption?
Yeah. Look, there's 103 centers of excellence or so maybe different at different centers. I'd say by and large, there was a preference early in the launch for prescribers to get individuals who don't have a therapy to try a therapy. The idea was, okay, I may have a group of patients on KUVAN, branded or generic. The data show that 100% of them should do better on SUFIANCE, but let them be for now. Let's start with those who don't have a therapy. In a way, that makes a lot of sense, right? Now we're starting to see, I think, and hear more and more of prescribers doing the work now to switch patients.
We commented a little bit on this dynamic at Q2 earnings when we said, we're seeing a little bit longer time to fill, because clearly now with payer policies in place, which have been very favorable, very flexible, but nonetheless, when you're going to switch someone from a less expensive drug to a more expensive drug, it's going to be a little bit more back and forth. As you know, that back and forth takes time from when you get a first request to fill to when ultimately getting that filled. I think what makes us so excited here is there's probably still about 2,500 patients on KUVAN in the country, branded or generic. As we said, we expect all of those patients to do very well on SUFIANCE.
I'm not saying 100% of them are going to get switched, but a lot of the prescribers said they expect over time that the vast majority of them would get switched. It's going to take a little bit of time, but we know when that switch occurs, going from one once a day well-tolerated therapy to another, that just simply provides greater benefit. That reads strong motivation for switching, both in terms of patients wanting it and prescribers wanting it. Two, adherence, right? You've already proven yourself adherent on a drug that's once a day in oral, now you're going to go to another drug that's once a day oral, but delivers more benefit.
Okay. Excellent. I think another thing heading into the launch, there was some estimates and expectations around kind of the average weight and the net price. Now that you've kind of have a year under your belt in the U.S., are those estimates still good? How do you think about the average price?
Yeah. I think we are pretty much where we thought we would be. We said in a ballpark, we priced it at the WAC was on based on a 45-kilogram patient. We said we expected to be in that ballpark of 45-50. That is where we are. I would say while the average age we said is about 17, 18, we are still getting a full spectrum of patients. In fact, I think we shared on the Q2 earnings call that we had one of the first newborns started, a very neonate started on SUFIANCE with outstanding results, so we see that as an area of growth and obviously lower weight, which is why the average does not tell the whole story. But I think overall, we are in the ballpark of those numbers where we thought we would be.
Okay. You touched on this earlier, but I think one of the other focal points, just when we look at some of the other PKU launches, is on the persistence rate. Again, with a number of months under your belt, how do you feel like the persistence rate of SUFIANCE is trending?
Yeah. We commented at Q2 that we were around 20% discontinuation rate. We felt we were getting pretty close to steady state. The reason for that is, looks like, again, what we have said is there has been a lot of things we thought at the time of launch that have gotten chewed up now. I think we assume that if someone was not responding to SUFIANCE, they would get probably a one-month trial and off, and what it seems like has been the case is it is closer to three months. So that is why we can just look at this now and say we are getting pretty close to steady state, and it reflects the experience in the clinical trials where we had over 75% of patients have greater than 15% phenylalanine lowering.
The other dynamic here that's super interesting, it relates back to the fact that early on we saw a lot of the therapy-naive patients. The reason they're therapy-naive, for the most part, is because there was a belief that they would not respond to KUVAN, meaning they had non-BH4 responsive classical PKU. They were the more severe patients. The fact that we had such a strong adherence rate early on in the most severe patients, also, we think bodes very well as we move forward and start getting more and more switching patients who we know definitionally are going to be responsive.
Excellent. Okay. Fantastic. That's the U.S. piece. You obviously have a lot of experience marketing medicines outside of the United States. How is the ex-U.S. kind of market unfolding? I realize it's sort of my territory, but what can you say about that?
It's going great. Look, we said that we believe we're at a point where we can see steady growth in the U.S. We believe that, and we'll have growth acceleration outside of the U.S. that will really kick into gear in the latter part of 2026 and into 2027 as we get pricing and reimbursement in more countries. Early on, the story has been Germany, Japan, and early access programs. Japan, we launched at the end of Q1, so we saw a really nice contribution in Q2 from Japan. That's a high-value market because pricing there is on par with the U.S., and while there's maybe 1,000 patients or so in Japan, the fact that the value for those patients is higher makes it a really valuable market for us. It's also a market where there's probably a higher proportion of patients on current therapies as well.
I think that's one where as a switching dynamic comes into play, we expect there to be a lot of room for growth in Japan. Germany was our first launch. That was July 15th of 2025, and that's following what we expected. It kind of fits and starts in terms of growth because in that first part, you're in that free pricing period where we had started a compassionate use program which gave us a small group of patients that were able to switch commercial as soon as we launched. We know that there's some reluctance in Germany sometimes for prescribers to start patients while the company is naming the price. They like there to be an agreed-upon price.
We saw a little bit of an uptake in the first half of the year, increased uptake in the first half of the year when we were out of the free pricing period. We expect once we have the final agreed-upon price in Germany, which we said will be before the end of this year, we'll probably see the next wave because that will signal to prescribers two really important things. One, that the price going forward is absolutely the government-sanctioned price, and the second, that we as a company are committed to staying in Germany. We've gotten feedback that there's a lot of concern that if companies don't get pricing that they want, they pull out of Germany.
Therefore, there's a reluctance to start patients on the therapy if the prescribers can't guarantee that the therapy's going to be there in a year from now. But we have every expectation that we'll land on a satisfactory agreed-upon price. Look, there's a lot of PKU patients in Germany, and their teams are working really hard there to make sure that as we can go deeper and deeper into launch, we really realize the market potential there. In other regions, we're using name patient programs. We're doing that in certain parts of Europe as well, Latin America, Middle East, other regions. I think as we move into 2027, we're going to be looking to get pricing and reimbursement in some of the major European markets. Also, we expect Brazil, where we have approval to start making contributions. As you know, the process there takes a very long time.
First, you leverage the judicialization process, which we put all things in place to be able to start to realize that, start getting group purchase orders as we move into 2027. Russia, Commonwealth of Independent States, we've gotten two recent approvals in the Middle East that we expect to be able to launch there in the near future. I think we're really pushing on and moving on all fronts globally, which is really, really exciting.
Okay. Fantastic. Just to double-click on that, when the German pricing is fully established, does that sort of kick off other European territories and pricing discussions?
We've started.
Okay.
We've already started with submitting dossiers in some of the larger European markets. There'll be other markets where we'll continue to rely on name patient for a while, just because that makes the most sense. Obviously, as you think about launch and launch sequence, one of the important things is that pricing corridor and trying to maintain a consistent list price, which goes into our whole strategy of how we sequence European markets, timing of pricing reimbursement discussions and the like.
Okay. Excellent. I want to move on to some of the other products, but just last question here. You have a lot of experience with Translarna outside of the U.S. Is that playbook essentially applicable in this case, or are you having to recreate the ex-U.S. playbook?
Yeah, 100% applicable. First of all, we had the infrastructure. If you just look at the timing as we face challenges with the sunsetting of Translarna outside the U.S. in many locations, it was really the perfect timing to say, "Okay, we've got PKU coming on. Let's start market development work." But the relationships with the medical centers, which tend to be similar specialty centers, the relationships with the HTA authorities, understanding the politics, understanding how things work in each of these countries, having the important content, the teams were all there, that experience, that infrastructure was built.
That's true in Europe, it's true in Latin America, it's true in Russia, Commonwealth of Independent States, Middle East. The one place where we had to build was Japan, which we did. It was fully built ahead of approval and ahead of launch, and I think the proof is in the pudding there. That launch is off to a great start.
Excellent. Okay. Well, very good. I guess speaking of Translarna and also EMFLAZA, how should we think about the evolution of those drugs through 2027?
Yeah, it's a great question. Look, you heard me at the beginning of 2026 say there's a couple things we know for certain this year. We know SUFIANCE is going to do great, but what we don't know, we know that also for certain that we're going to see continuing decline in Duchenne franchise, and we have. But still with reasonably solid revenue contributions. I think EMFLAZA is now ticking along between $20 million to $25 million the first two quarters. We've actually saw some patient starts, which is really odd when you have 10 generics on the market, having over two years ago lost exclusivity. And we said all along, look, we believe we can continue to deliver revenue from EMFLAZA until one of the generics drastically cuts the price, then you get to the race to the bottom. It's hard to predict when that's going to happen.
As I know Pierre always says, they do not give us a heads up when they are going to cut the price. But for now, we are going to continue to deliver, and we have got really great relationships in the patient community. I think this is a point also I should highlight. Our PTC Cares patient services team, which has been so important to the brand loyalty for EMFLAZA, but is also now a central part of the SUFIANCE story, really going out there and working with patients and prescribers to make sure we get patients on drug and they stay on drug. And that team has been really important in what we have been able to do with EMFLAZA as well.
On the Translarna side, look, we are selling the drug without a license in Europe. There is no precedent for that. We expect over time that that revenue should continue to erode. Countries where we get large purchase orders like Russia, like Brazil, we have gotten them this year. Unclear if we will get other ones this year or any going forward. So a long way say I cannot predict what it is going to be, but I expect that revenue will decline over time.
Okay. That is great. And maybe turning to votoplam and Huntington's disease, we have seen there is a lot of news flow just in the Huntington's disease sector, especially in the biotech sector. Talk about your strategy here, and what is the goal of maybe connecting with the FDA ahead of the phase III readout?
Yeah, absolutely. Look, we made very clear after we shared what we believe are very solid results from the 24-month long-term extension that we and Novartis, our partner, would discuss whether we'd meet with the FDA with the news that the gene therapy was given the green light to submit an application for accelerated approval based on cUHDRS as-
As uniQure's gene therapy.
Yep.
Yep.
As cUHDRS as an intermediate clinical endpoint. That was obviously a very important data point for us in making our plans because we said, look, not only do we have very good results at 24 months, slowing progression over 50% in what we expect will be the ultimate dose. We've got a much larger number of patients who've been treated. We have a better defined safety profile. Unlike the gene therapy, we actually have objective measurement of target engagement and mHTT protein reduction. That's usually what you see with the gene therapy that gives you confidence in the gene therapy, but just given the fact that it's locally delivered to the brain and ours is systemic, we're actually now able to have that with the small molecule. The confirmatory study is up and running.
It's been agreed upon, and it's up and running, and obviously, it's reversible, titratable if new things are learned. We think when you put that constellation of data together, it's certainly worth a discussion to say, "Hey, FDA, if you're willing to accept an accelerated approval endpoint over in CBER on a small number of patients without these features and not having any placebo-controlled data that we had where the placebo and natural history perform like each other," it's worth having that discussion in CBER. I think Novartis has been very clear, though, that their base case is phase III. It has an interim analysis to get to an answer sooner, if it goes that far. Look, I think it's just reasonable to have that discussion and get the FDA's feedback, and that'll happen in the second half.
Okay. Excellent. Very good. I also want to turn to the Friedreich's ataxia program, where you also had some recent FDA feedback. I guess maybe frame that and also frame the commercial opportunity as you see it.
Yeah, absolutely. Look, I think we were quite clear that we believe the data package for vatiquinone supported approval last year. I think FDA took a very strict view statistically, and that was really in our discussions, what came out as the reason they just couldn't get comfortable approving it since we had only hit on a component of the primary endpoint, even though that was separately specified as an endpoint. They made it clear that they wanted an additional study to support approval. They suggested that that study could be an open label study with natural history comparison. We were a bit pleasantly surprised by that. But I think when you consider that the safety profile of the drug is very well characterized, it's very safe, it's demonstrated to be very safe and well-tolerated, especially in children.
The data did show evidence of a benefit that really needed to be confirmed. FDA has used the Friedreich's ataxia natural history registry to support the previous approval of Reata's drug or SKYCLARYS, which is now Biogen's drug. So I think they trusted that as a source of comparator. We went, I guess, under the heading of trust and verify. We went ahead and developed a protocol, a statistical analysis plan of how we would actually do the natural history comparison group, what would be the model, the matching model, what would be the analyses. Brought those to FDA, met with FDA, got feedback which we could easily incorporate, and now we're getting ready to start that trial this quarter. We said about 120 individuals aged 7- 21, same inclusion criteria as we had for the MOVE-FA phase III trial.
Again, I think given all of our learnings in FA, given the fact that we have a very good understanding what that natural history comparator arm should do in terms of progression over the 24 months, and we believe this is a very high probability of success study.
Okay.
In terms of market opportunity, we've said all along that this is a therapy that while has been studied a lot in children, could be a therapy both for children and adults with FA. I think there's still a wide open opportunity for pediatric patients, and clearly there's enough room for another treatment option for adults in FA, especially one that we wouldn't expect would carry some of the monitoring requirements that SKYCLARYS requires.
I see. Excellent. I also want to touch on, you recently acquired an asset, ST-920 for Fabry. I guess number one, talk about what attracted you to that asset.
Yeah. We had talked all along about one of our objectives this year was to explore business development as a way to leverage our global commercial infrastructure, which has clearly demonstrated itself again to be quite capable and quite accomplished, but certainly has capacity. We've been continually looking for rare disease opportunities that we think could fit in quite well. This one came a little bit out of, I'll say out of the blue, but it was a kind of a unique situation through the bankruptcy proceeding where we became aware that this was a BLA stage asset. The clinical data looked good, sounded like very. What we found on diligence was that the CMC pack, CMC was in good order. We certainly know how to commercialize gene therapies. We certainly know how to get gene therapies approved.
We had one of the first AAV therapies that got approved with Upstaza. We believe there's a very real market opportunity here. The standard of care for Fabry is enzyme replacement therapy. That is the standard of care. There's two approved enzyme replacement therapies in the U.S., an additional one outside of the U.S. Heavy burden for some individuals. It's every other week administration. It requires pre-treatment immunosuppression. Patients over time can develop antibodies that can then reduce the effectiveness of the enzyme replacement therapy. The value proposition of having a one-time single administration, no immunosuppression required, safe and well-tolerated enzyme replacement, we thought was really special. We pursued it, and then the ability to bring in a BLA stage asset for $100 million-$110 million, we thought was again pretty unique. We're still doing our work on what the market opportunity is here.
Just looking at some of our initial estimates and what some of the analyst estimates were for the gene therapy in previous years. We have every reason to believe this could be $700 million, $750 million. Potentially even higher peak global opportunity for us. When you put all that together, obviously a lot to be excited about. We expect to close the deal in the next couple of weeks, and expect, as we said previously, to have the BLA submitted by the end of this year.
That's great. The one thing you mentioned is it's a global opportunity. How important is that ex-U.S. piece to the kind of commercialization of this?
I think it's important. I think the U.S. is going to be the majority of that opportunity. Clearly, as we told our teams and our commercial teams, everyone's super excited. I should say, in part, we have a lot of in-house Fabry commercial experience from just previous companies. A lot of folks who worked on Replagal back in the day, and some who've worked on Fabrazyme. We've got a lot of folks around the company who know Fabry, know the patient community really well, and are so excited about this opportunity.
But we said, "Look, let's focus. First things first, let's get that BLA in." We will go ahead. We're working on right now just the sequence of how we pursue registration in other countries, launch in other countries. How do we leverage the inpatient? Again, as you've alluded to before, our playbook, which has demonstrated to be quite successful in a number of different launches.
Okay. The ink is obviously still wet here, and you submitted, we're getting close to closing, but what have you said about what's needed to file the BLAs? Are there any other things that you need to check off as a company before doing that?
Yeah. Sangamo initiated a rolling submission. They've already submitted components of it. The last major piece is CMC. I think we know from our own experience, and everyone who knows looks at gene therapy, CMC is a big one. We obviously did a lot of diligence work on that to give us confidence that this is a solid package. There's just going to be some work to do to put that together and get that filing in. Rest assured, we're also going to look over every aspect of the BLA and make sure this is as solid a submission as possible.
Okay. Excellent. In the last few minutes or so, I want to go through some of the kind of earlier stage pipeline programs. Maybe we can start with the MSH3 and maybe just high level, why have another potential Huntington's program?
Yeah. Look, we're super excited about MSH3 for a number of reasons. This comes from our splicing platform. We talked a lot about at our R&D Day last year that we've made a number of advances in splicing. Clearly pioneered the field with Evrysdi. Votoplam then came along as a second therapy. Both have demonstrated to be highly valuable therapies. One of the things that we did internally a couple of years ago was say, "We've got basically this well-differentiated, validated, and valuable RNA technology, small molecule splicing, particularly well-suited for CNS disorders, where ASOs and siRNA can be sort of distribution limited for obvious reasons. Let's focus on this. Let's really cultivate this platform.
We think it can be incredibly valuable for neurological disorders, as well as other disorders which may or may not be core to PTC that we can use as a source of strategic partnering. The MSH3 program is sort of the first product of that. From start to D.C. nomination took us about three and a half years, which is warp speed compared to what Evrysdi and votoplam took. We are really excited because MSH3 is an important target for somatic expansion, not only for Huntington's disease, but also for other disorders like myotonic dystrophy, for example, and there are a number of triplet repeat disorders. This is a first for us in splicing, where we can have a target that could be useful in a number of disorders.
In terms of specifics to HD, it is a different mechanism than HTT lowering. It is a different target. It is a different dinucleotide sequence. Again, showing a little bit how we have evolved the splicing platform that we can achieve sequence specificity, not just with the sequences we used for votoplam and Evrysdi, but now a whole different set of targets. We think this could also be one that is particularly well-suited for juvenile HD, where you have very rapid expansion of the CAG repeat, which is why it is such an aggressive early onset disease. So, at the very least, it is complementary to HTT lowering, but we also think that there could be specific populations, i.e. juvenile HD, where it is particularly well-suited.
Okay. Fantastic. Then, as you think about kind of the clinical, I guess, what is the clinical kind of plan? Like when would you progress into phase I, phase II?
Yeah, absolutely. We are in the process of doing the IND-enabling pharm tox now. We have said we expect to be in phase I next year, and we will pull the page out of the Evrysdi playbook, if you will, which we did for votoplam, which is use phase I to not only collect the important pharmacology and safety data but also begin to leverage the fact that we can measure mRNA and protein changes in peripheral blood cells, just to give us an early read on PK/PD and validation of target engagement. Our teams are already in the background doing the work of thinking as well about what are potential biomarker strategies we can leverage as we move forward that could potentially open up an accelerated approval pathway as we move into phase II and beyond.
Excellent. You have a lot of programs, but I think that the other one that I wanted to make sure we hit on is the NLRP3 program. What is the opportunity there?
We are very excited about this. Look, I think when we talked about our inflammation platform, we said, look, the idea is there is a number of targets that are known to be biologically important, and the question is, can we develop differentiated molecules, differentiated in terms of safety, target specificity, and potency? NLRP3 PTC612, we believe ticks all those boxes. As we shared again last year at our R&D day, that it benchmarks quite well against other NLRP3 molecules in terms of potency. It has a slightly different chemical scaffold than a number of the others that were associated with some of the side effects, so we believe we could have a better tolerability profile.
We said in terms of indications, we are planning to prioritize rare pulmonary indications for the simple reason that if you look at that Venn diagram of NLRP3 inflammasome activity and disease pathology, there is a lot of overlap there, both in terms of inflammation and fibrosis, which are really the two legs of the NLRP3 story. We are in phase I right now. We mentioned that as part of the MAD portion of the phase I study, we are going to be enrolling a cohort of individuals with metabolic syndrome, basically to allow us in phase I to just start to get an understanding of what we are seeing in terms of exposure, NLRP3 activity, and effect on some biomarkers that we know will be important in the store as we move forward into phase II.
Okay. Fantastic. Maybe if I could just ask kind of a broader sort of just company-level question. Obviously, there's a lot of R&D and interesting things kind of coming out of the pipeline, but how do you think about, is the goal near term to drive revenue? I guess, how do you think about goals in terms of cash flow positivity and profitability and kind of what should be the expectation for investors?
Well, we said we could be cash flow breakeven this year, number one. Profitability was very important to us when we started actually to reset the company a number of years ago. Actually, revenues are growing, OpEx has been reduced, right? That's very important to us. We want to build a diversified, sustainable business. You have to be profitable, no question. Rest assured that despite the fact that we have a number of early-stage programs coming and new development assets, there's also the old programs coming out. For instance, HD, full phase III, Novartis base, all of it, as an example. We said we're going to be very disciplined with OpEx, and that's what we've been doing.
In any way we look at a company, that's how we think about it. Business development, for instance, we said we're going to be disciplined. It's very important when we look at it. We want to create value for shareholders. That's how we think about all those programs.
Okay, fantastic. Well, very good. I just want to turn to the audience. Are there any questions from the audience? All right, I think we did a good job.
Thank you.
Thank you all.
Thank you.